Marjilla Seddiq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marjilla Seddiq has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bindu Kanapuru
U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research Silver Spring, Maryland
1 shared publication - Bronwyn D. Mixter
Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD
1 shared publication - Daniel L. Suzman
U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research Silver Spring, Maryland
1 shared publication - Gulsum E. Pamuk
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
1 shared publication - Harpreet Singh
Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD
1 shared publication Jennifer Lafferty
Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI, USA
1 shared publication
Latest Publications
- 12 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2515-2524
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
- 12 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2515-2524
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
- Open Access
- 8 June 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (4) , E239-E242
Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim
- 8 June 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (4) , E239-E242
Open AccessSevere macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim